Saltar al contenido principal

The Centers for Medicare and Medicaid (CMS) Release Billing Guidelines for COVID-19 Vaccine

WellCare of New Jersey is closely following advancements in the prevention and treatment of COVID-19, including vaccinations. As a healthcare provider, you will play an integral role as COVID-19 vaccines become available. We want to update you on important new information about vaccine coverage.

To prepare for vaccine administration, the Centers for Medicare and Medicaid (CMS) have published billing guidance (PDF) for Medicaid and Children’s Health Insurance Program (CHIP) providers. Similar to other COVID-19 services, the vaccines will be offered at no cost to your patients. In addition:

  • WellCare of New Jersey will configure its systems to properly adjudicate COVID-19 vaccine-related claims, both for the vaccine and its administration, in accordance with New Jersey’s coverage determinations for Medicaid beneficiaries
  • La responsabilidad de los miembros será de $0
  • Non-participating provider pre-auth requirements will be waived
  • Las tasas de reembolso a los proveedores y las autorizaciones de uso de emergencia (EUA) continúan pendientes, por lo que le informaremos a medida que dicha información esté disponible

The American Medical Association (AMA) has published updates to the Current Procedural Terminology (CPT®) code set that includes new vaccine-specific codes to report immunizations for the novel coronavirus (SARS-CoV-2). The code set will continue to be updated as additional vaccines receive EUA approval by the U.S. Food & Drug Administration (FDA).

The following codes have been published as of November 10, 2020. However, they will not be billable until the specific vaccine receives official EUA approval.

Código

Descriptor breve de CPT

Nombre del etiquetado

Nombre de la vacuna/del procedimiento

91300

SARSCOV2 VAC

30MCG/0.3ML IM

Pfizer

Vacuna contra el COVID-19 de Pfizer-Biotech

0001A

ADM SARSCOV2 VAC

30MCG/0.3ML 1ST

Pfizer

Vacuna contra el COVID-19 de Pfizer-Biotech

Administración – Primera dosis

0002A

ADM SARSCOV2 VAC

30MCG/0.3ML 2ND

Pfizer

Vacuna contra el COVID-19 de Pfizer-Biotech

Administración – Segunda dosis

91301

SARSCOV2 VAC

100MCG/0.5ML IM

Moderna

Vacuna contra la COVID-19 de Moderna

0011A

ADM SARSCOV2 VAC

100MCG/0.5ML 1ST

Moderna

Vacuna contra la COVID-19 de Moderna

Administración – Primera dosis

0012A

ADM SARSCOV2 VAC

100MCG/0.5ML 2ND

Moderna

Vacuna contra la COVID-19 de Moderna

Administración – Segunda dosis

Additionally, CMS has also published a set of toolkits to help providers prepare to swiftly administer the vaccine once it is available. If you have any further questions about this upcoming vaccine or the COVID-19 services WellCare of New Jersey covers, please contact Provider Services at 1-888-453-2534.

Documentos útiles

Starting in mid-December and continuing into early 2021, vaccine access will be given to New Jersey's Phase 1A Group:

New Jersey utiliza un enfoque en fases para la vacunación contra el COVID-19 para garantizar que las vacunas limitadas se distribuyan de manera justa y equitativa.

Tenga en cuenta que las siguientes ubicaciones están disponibles para que los trabajadores de la salud pidan una cita para recibir una vacuna. Los centros de vacunación verificarán que usted sea un trabajador de la salud antes de administrarle la vacuna y se requerirá la documentación adecuada.

Ícono de contacto

¿Necesita ayuda? Puede contar con nosotros.

Contáctenos
Y0020_WCM_178064E_M Última actualización: 11/10/2025